ATE500752T1 - Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom - Google Patents

Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Info

Publication number
ATE500752T1
ATE500752T1 AT05722048T AT05722048T ATE500752T1 AT E500752 T1 ATE500752 T1 AT E500752T1 AT 05722048 T AT05722048 T AT 05722048T AT 05722048 T AT05722048 T AT 05722048T AT E500752 T1 ATE500752 T1 AT E500752T1
Authority
AT
Austria
Prior art keywords
treatment
insulin resistance
sphingolipids
prevention
type
Prior art date
Application number
AT05722048T
Other languages
German (de)
English (en)
Inventor
Willem Nieuwenhuizen
Aloysius Havekes
Josephus Emeis
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34975255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE500752(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP04075848A external-priority patent/EP1576894A1/en
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE500752T1 publication Critical patent/ATE500752T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05722048T 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom ATE500752T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075848A EP1576894A1 (en) 2004-03-16 2004-03-16 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
EP04077088 2004-07-19
PCT/NL2005/000193 WO2005087023A1 (en) 2004-03-16 2005-03-15 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome

Publications (1)

Publication Number Publication Date
ATE500752T1 true ATE500752T1 (de) 2011-03-15

Family

ID=34975255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722048T ATE500752T1 (de) 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Country Status (7)

Country Link
US (3) US20070207983A1 (https=)
EP (1) EP1729597B1 (https=)
JP (1) JP5154218B2 (https=)
AT (1) ATE500752T1 (https=)
AU (1) AU2005220692A1 (https=)
DE (1) DE602005026785D1 (https=)
WO (1) WO2005087023A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US8003617B2 (en) * 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
PL2032134T3 (pl) 2006-05-09 2015-11-30 Genzyme Corp Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów
US20090117198A1 (en) 2006-05-31 2009-05-07 Hiroshi Kawakami Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
ES2660690T3 (es) 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
US8178515B2 (en) * 2008-10-08 2012-05-15 Nucitec S.A. De C.V. β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof
JP5689055B2 (ja) * 2009-05-13 2015-03-25 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP6169978B2 (ja) * 2012-01-25 2017-07-26 株式会社Ｊ−オイルミルズ スフィンゴイド塩基を含む抽出物の製造方法
US9492466B2 (en) 2012-06-14 2016-11-15 Nucitec S.A. De C.V. Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CA3158256A1 (en) * 2019-11-13 2021-05-20 Aimee EDINGER Drug formulations and methods of treatment for metabolic disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP3157531B2 (ja) * 1991-03-08 2001-04-16 昭和産業株式会社 血中コレステロール低下剤
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
ATE286735T1 (de) * 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
JP2001527046A (ja) * 1997-12-30 2001-12-25 エイプラス サイエンス インベスト アーベー ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
CA2362549A1 (en) * 1999-02-24 2000-08-31 John Hopkins University Compositions and methods for modulating serum cholesterol
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) * 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
AU784722B2 (en) * 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2001072701A1 (en) * 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
JP2002226394A (ja) * 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
JP4958339B2 (ja) * 2001-03-21 2012-06-20 雪印メグミルク株式会社 脂質代謝改善剤
DK1406641T3 (da) * 2001-06-18 2009-05-04 Neptune Technologies & Bioress Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4568464B2 (ja) * 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
AU2003239489A1 (en) * 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
EP1585508B1 (en) * 2003-01-20 2009-04-01 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels
JP4585172B2 (ja) * 2003-01-31 2010-11-24 森永乳業株式会社 骨形成促進剤
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP4341891B2 (ja) * 2003-03-05 2009-10-14 森永乳業株式会社 血糖降下組成物
AU2003217508A1 (en) * 2003-03-07 2004-09-28 Korea Atomic Energy Research Institute A composition comprising phytosphingosine or a derivative thereof

Also Published As

Publication number Publication date
US20090203651A1 (en) 2009-08-13
JP5154218B2 (ja) 2013-02-27
AU2005220692A1 (en) 2005-09-22
EP1729597B1 (en) 2011-03-09
US20110003772A1 (en) 2011-01-06
EP1729597A1 (en) 2006-12-13
US20070207983A1 (en) 2007-09-06
DE602005026785D1 (de) 2011-04-21
WO2005087023A1 (en) 2005-09-22
JP2007529507A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE500752T1 (de) Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
TW200602043A (en) Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
TW200730540A (en) Novel peptide compounds
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
RU2010143817A (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
MY142807A (en) Benzimidazole derivative and use thereof.
DE502004002556D1 (de) Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
CA2304713A1 (en) Biphenyl-5-alkanoic acid derivatives and use thereof
BR0317703A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
MY151072A (en) Heteroaryl derivative
TW200724136A (en) Pharmaceutical compositions comprising PPAR modulator
DE602004030004D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
ATE391730T1 (de) Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
GEP20104882B (en) Age inhibitors
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200744589A (en) Pharmaceutical composition
AR044175A1 (es) Compuestos de cefemo
EP2055188A4 (en) AGENT FOR INCREASING THE POLYPHENOL CONTENT OF PLANTS
WO2007033039A3 (en) Proteasome inhibiting beta lactam compounds
MX2009006094A (es) Uso de derivados canfolenicos como ingredientes fragantes en perfumeria y saborizacion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties